20230414-中国银河-迪安诊断-300244.SZ-计提较为充分_期待主业ICL增长_10页_940kb

Diandian Diagnosis (300244SZ) 2022 Report Summary

Key Points:

• Diandian Diagnosis, a leading third-party medical testing provider, reported strong performance in 2022 with high growth driven by diagnostic services and product business expansion.

Financial Performance

• 2022 revenue reached 20.282 billion CNY, up 55.03%.
• Net profit was 143.4 billion CNY, up 23.33%, with non-GAAP profit of 162.9 billion CNY, up 49.05%.
• EPS was 2.29 CNY for 2022. Fourth-quarter results showed net loss due to aggressive provisions.

Business Segments

Diagnostic Services

• Core business grew steadily; excluding COVID-related revenue, routine services increased 154.7% following pandemic disruptions.
• Total services revenue was 126.74 billion CNY, with significant contribution from COVID testing.

Product Business

• Self-produced products generated 15.33 billion CNY in revenue, up sharply.
• Channel products contributed 78.65 billion CNY, seen steady growth.

Growth Drivers

• Network expansion: "1+4+35+43+650+" lab layout enhanced coverage.
• Operational efficiencies through AI and automation.
• New product developments in molecular diagnostics, cell pathology, and other areas.

Financial Outlook

• 2023-2025 financial projections: Revenue CNY 47.14B-95.15B; profit CNY 19.10B-165.0B; EPS 1.68-2.63 CNY.
• P/E ratios expected to decrease to 11 times by 2025; current valuation supports investment recommendation.

Analyst Recommendation

• Maintain "Recommend" rating based on growth prospects.
• Key risks include slower-than-expected business recovery and credit issues.